Outcome
Price
▲ positive · ▼ negative · ● neutral filings · teal = economic event · numbered = multiple that day (click to pick). Times IST.
On the reaction day the stock moved 2.7 pts more than Nifty Microcap 250 and 2.2 pts more than its Other Financial Services peers, over the same two closes: a difference in percentage points, not a measure of what the filing did.
Minute windows have no benchmark: there is no intraday index history to compare against.
Arunjyoti Bio Ventures reported its Q2 FY26 results on 3 November 2025, showing a sharp swing to a loss. Revenue from operations fell to ₹533.65 lakhs from ₹871.24 lakhs in the previous quarter, while the company posted a net loss of ₹122.73 lakhs versus a profit of ₹204.54 lakhs in Q1 FY26. For the half-year, revenue declined to ₹1,404.89 lakhs from ₹1,644.89 lakhs in H1 FY25, with net profit halving to ₹81.81 lakhs. The auditor (PKF Sridhar & Santhanam LLP) issued an unmodified review report but included an Emphasis of Matter regarding a prior-period deferred tax correction that led to restated comparative figures. Total equity stood at ₹3,387.47 lakhs with borrowings of ₹2,357.59 lakhs, and operating cash flow remained positive at ₹790.63 lakhs.
The sharp quarter-on-quarter revenue drop and swing to a loss are negative signals for shareholders, suggesting weaker business momentum in Q2 FY26. However, the restatement is non-cash and the half-year remains profitable, so the long-term picture is less alarming.